Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment

Overview

Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.

Full Title of Study: “Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2010

Interventions

  • Drug: Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
    • 2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.

Clinical Trial Outcome Measures

Primary Measures

  • Carrier Rate for Staphylococcus Aureus
    • Time Frame: Baseline
    • Percentage of subjects with baseline culture positive for Staphylococcus aureus (via nasal swab)
  • MSSA Clearance Rate
    • Time Frame: 14 days
    • Percentage of subjects with methicillin-sensitive S. aureus on Baseline culture who achieved clearance with treatment.
  • MRSA Clearance Rate
    • Time Frame: 14 days
    • Percentage of subjects with methicillin-resistant S. aureus on Baseline culture who achieved clearance with treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • Willing and able to give informed consent – Must have consented prior to registration for the study Exclusion Criteria:

  • active infection – concurrent treatment with antibiotics, topical or systemic – S. aureus decolonization attempt in prior six months – history of HIV – chemotherapy or systemic immunosuppressive therapy – history of neomycin allergy or sensitivity

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Northwestern University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dennis West, Professor in Dermatology and Pediatrics – Northwestern University
  • Overall Official(s)
    • Peter Lio, MD, Principal Investigator, Northwestern Unviersity

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.